epoch
Showing 1 - 6 of 6
Hodgkin Lymphoma, DLBCL Trial run by the NCI (campath, Rituximab, EPOCH)
Completed
- Hodgkin Lymphoma
- Diffuse Large B-Cell Lymphoma
- Campath
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 11, 2022
DLBCL (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma Trial run by the National Cancer Institute (NCI)
Active, not recruiting
- Diffuse Large B-Cell Lymphoma (DLBCL)
- +4 more
- EPOCH
- Rituximab
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Lymphoma, AIDS-related, Lymphoma, Large B-Cell, Diffuse Trial run by the NCI (Rituximab, Filgrastim, EPOCH)
Active, not recruiting
- Lymphoma, AIDS-related
- Lymphoma, Large B-Cell, Diffuse
- Rituximab
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Jul 21, 2022
AIDS Related Lymphoma, AIDS-Associated Lymphoma Trial run by the NCI (Filgrastim, Rituximab, EPOCH)
Completed
- AIDS Related Lymphoma
- AIDS-Associated Lymphoma
- Filgrastim
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Jan 18, 2022
Lymphoma, T-Cell, Lymphoma, Extranodal NK-T-Cell Trial run by the NCI (Alemtuzumab (Campath), EPOCH)
Completed
- Lymphoma, T-Cell
- Lymphoma, Extranodal NK-T-Cell
- Alemtuzumab (Campath)
- EPOCH
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Feb 3, 2022
Lymphoma, Mantle Cell, Mantle Cell Lymphoma Trial run by the NCI (Rituximab (R), EPOCH, Bortezomib (B))
Active, not recruiting
- Lymphoma, Mantle Cell
- Mantle Cell Lymphoma
- Rituximab (R)
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 21, 2021